Equities research analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report ($0.06) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for AVEO Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.05). AVEO Pharmaceuticals posted earnings per share of ($0.15) during the same quarter last year, which would suggest a positive year over year growth rate of 60%. The company is expected to issue its next earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that AVEO Pharmaceuticals will report full-year earnings of ($0.16) per share for the current year, with EPS estimates ranging from ($0.21) to ($0.11). For the next year, analysts forecast that the company will report earnings of ($0.15) per share, with EPS estimates ranging from ($0.18) to ($0.10). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover AVEO Pharmaceuticals.
AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $1.61 million during the quarter, compared to analyst estimates of $0.74 million. AVEO Pharmaceuticals had a negative return on equity of 24.50% and a net margin of 70.30%.
A number of hedge funds have recently modified their holdings of AVEO. HCR Wealth Advisors purchased a new position in shares of AVEO Pharmaceuticals during the 1st quarter worth $28,000. WealthTrust Axiom LLC grew its position in shares of AVEO Pharmaceuticals by 390.5% during the first quarter. WealthTrust Axiom LLC now owns 138,505 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 110,270 shares in the last quarter. SG Americas Securities LLC purchased a new stake in AVEO Pharmaceuticals during the first quarter worth approximately $50,000. Excalibur Management Corp lifted its stake in AVEO Pharmaceuticals by 363.6% during the first quarter. Excalibur Management Corp now owns 51,000 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Virtu Financial LLC lifted its stake in AVEO Pharmaceuticals by 105.5% during the first quarter. Virtu Financial LLC now owns 139,585 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 71,667 shares during the last quarter. Hedge funds and other institutional investors own 28.33% of the company’s stock.
Shares of AVEO Pharmaceuticals stock traded down $0.01 during trading on Friday, reaching $0.71. The company’s stock had a trading volume of 1,925,446 shares, compared to its average volume of 5,085,601. AVEO Pharmaceuticals has a one year low of $0.49 and a one year high of $3.59. The company has a market cap of $115.89 million, a price-to-earnings ratio of -3.74 and a beta of 0.88. The stock has a fifty day moving average price of $0.72.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Recommended Story: What is the accumulation/distribution indicator?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.